Xconomy: Alector Snags $133M to Activate Immune Cells Against Neurodegeneration
Xconomy - 2018-07-25
Pharmaceutical companies have been working for years to find a drug that could break up the toxic clusters of proteins associated with Alzheimer’s disease and other neurodegenerative disorders. Many of those companies have suffered disappointingfailuresby targeting those clusters head-on. Now a Bay Area biotechnology company,Alector, is ready to try tackling the problem from a different angle— energizing immune system cells, the body’s natural clean-up crew, to clear away the debris.